BrainVectis
www.brainvectis.comBrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), BrainVectis is hosted at MIRCen (CEA, Fontenay aux Roses).
Read more
BrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), BrainVectis is hosted at MIRCen (CEA, Fontenay aux Roses).
Read more
Country
City (Headquarters)
Paris
Industry
Employees
1-10
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Head of the Preclinical Research Office - Brainvectis Therapeutics
Email ****** @****.comPhone (***) ****-****
Technologies
(11)
Reach decision makers at BrainVectis
Free credits every month!
BrainVectis FAQ
Paris, France
Biotechnology Research
